Alector News and Activities

Alector is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Alector is a company listed under the stock ticker ALEC (US).

View the org chart displaying its 20 main executives

Most searched biographies at Alector

• Arnon Rosenthal, Co-Founder, Chief Executive Officer and Director
• David Wehner, Director
• Richard Scheller, Director

Popular executive movements at Alector

• Neil Berkley who was Interim Chief Financial Officer and Chief Business Officer, becomes Chief Financial Officer and Chief Business Officer  (posted on December 15 2025).
• Kristina Cutter, who was Chief Regulatory, Pharmacovigilance and Quality Assurance Officer, is promoted to Chief Development Officer  (posted on December 1 2025).
• Sara Kenkare-Mitra, President and Head of Research and Development, will leave the company on Dec. 22, 2025  (posted on October 23 2025).

Create your alert
to follow the executive moves at Alector.

Alector has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Alector

• Alector to Participate at Virtual Investor Conferences in September | Alector
• Alector Reports Second Quarter 2020 Financial Results and Provides Corporate Update | Alector
• Alector to Present at the BTIG Virtual Biotechnology Conference 2020 | Alector
• Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal Dementia | Alector
• Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal Dementia | Alector
• Alector to Present Data from the AL001 Phase 2 Open-Label Study in Frontotemporal Dementia at the 2020 Alzheimer’s Association International Conference | Alector
• Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002, a TREM2 Activating Antibody for the Treatment of Alzheimer’s Disease, in The Journal of Experimental Medicine | Alector
• Alector to Present at the Goldman Sachs 41st Annual Global Healthcare Conference | Alector
• Alector Reports 2020 First Quarter Financial Results and Business Highlights | Alector
• Alector to Present at the Bank of America Securities Virtual Health Care Conference | Alector
• View more press releases Close

Social media about Alector

• Alector on Wikipedia, Google News & Yahoo Finance
• Alector on LinkedIn, X (Twitter) & YouTube